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Background: Sinusoidal obstruction syndrome (SOS), a form of drug-induced liver injury 
related to oxaliplatin treatment, is associated with postoperative morbidity after 
hepatectomy. This study aimed to examine the impact of regorafenib, the first 
small-molecule kinase inhibitor to show efficacy against metastatic colorectal cancer, on a 
rat model of SOS. 
Methods: Rats with monocrotaline (MCT)-induced SOS were divided into 2 groups 
according to treatment with either regorafenib (6 mg/kg) or vehicle alone, which were 
administered at 12 and 36 h, respectively, before MCT administration. Histopathological 
examination and serum biochemistry tests were performed 48 h after MCT administration. 
Sinusoidal endothelial cells (SECs) were evaluated by immunohistochemistry and electron 
microscopy. To examine whether regorafenib preserved remnant liver function, a 30% 
hepatectomy was performed in each group. 
Results: The rats in the vehicle group displayed typical SOS features, whereas these 
features were suppressed in the regorafenib group. The total SOS scores were significantly 
lower in the regorafenib group than in the vehicle group. Immunohistochemistry and 
electron microscopy showed that regorafenib had a protective effect on SECs. The 
postoperative survival rate after 7 days was significantly better in the regorafenib group 
than in the vehicle group (26.7% vs. 6.7%, p < 0.05). Regorafenib reduced the 
phosphorylation of extracellular signal-regulated kinase (ERK), which induced MMP-9 
activation and decreased the activity of matrix metalloproteinase-9 (MMP-9), one of the 





Conclusions: Regorafenib suppressed MCT-induced SOS, concomitant with attenuating 
ERK phosphorylation and MMP-9 activation, suggesting that regorafenib may be a 
favorable agent for use in combination with oxaliplatin-based chemotherapy. 
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The liver is the most frequent site of metastasis from colorectal cancer (1,2). Surgical 
resection is considered the only curative therapy for colorectal liver metastasis (CLM) 
(3,4); however, only 25% of patients are eligible for hepatic resection with a curative intent 
(5,6). Recently, new anticancer drugs including oxaliplatin have improved treatment results 
for colorectal cancer and enabled patients with initially unresectable CLM to undergo 
hepatic resections after neoadjuvant chemotherapy (7). Despite its benefits, however, 
preoperative oxaliplatin-based chemotherapy for CLM induces damage in the nontumorous 
liver parenchyma, known as sinusoidal obstruction syndrome (SOS) (8,9), which is 
characterized by sinusoidal dilatation, endothelial damage in the central vein, and 
coagulative necrosis of hepatocytes (9). In patients with CLM, SOS contributes to 
postoperative morbidity after hepatectomy (10); therefore, a strategy to control SOS needs 
to be developed.  
In a rat model of monocrotaline (MCT)-induced SOS, matrix metalloproteinase-9 
(MMP-9) was described as a key mediator in the development of SOS (11,12). In fact, 
MMP inhibitors have been shown to block the progression of SOS in the animal model, but 
the detailed mechanism has not been elucidated (12). We previously reported that sorafenib, 
a multikinase inhibitor, also attenuated MCT-induced SOS via MMP-9 suppression (13). 
However, a phase IIb study did not show a benefit in progression-free survival with the 
addition of sorafenib to oxaliplatin-based chemotherapy (14). Therefore, further clinical 
trials of sorafenib for colorectal cancer have not been conducted, indicating that future 





Regorafenib is a novel oral multikinase inhibitor that targets various protein kinases 
such as vascular endothelial growth factor receptors (VEGFR) 1/2/3, tyrosine kinase with 
immunoglobulin and epidermal growth factor homology domain 2 (TIE-2), platelet-derived 
growth factor receptor-beta (PDGFR-beta), c-kit, ret, raf-1, and B-RAF (15). An 
international phase 3 trial (CORRECT) demonstrated a statistically significant 
improvement in overall survival and progression-free survival when regorafenib was 
administered to patients with metastatic colorectal cancer that progressed after all other 
approved standard therapies (16). On the basis of this trial, regorafenib was approved for 
metastatic colorectal cancer in several countries, including the US, Canada, Europe, and 
Japan. Furthermore, a phase 1b study of combined therapy with regorafenib and 
oxaliplatin-based chemotherapy has been reported (17). Wilhelm et al. showed that 
regorafenib inhibited the phosphorylation of extracellular signal-regulated kinase (ERK), 
which is reported to be necessary for MMP-9 activation (15,18). Thus, regorafenib also has 
the potential to attenuate SOS, similarly to sorafenib. However, it would be premature to 
conclude that regorafenib has a protective effect against SOS in the way sorafenib does, 
because the structure of regorafenib differs from that of sorafenib, resulting in a different 
biochemical profile from sorafenib (15).  
The purpose of the present study was to examine the impact of regorafenib on SOS in 
a rat model and to clarify whether regorafenib improves mortality after hepatic resection.  
 






Monocrotaline (MCT) was purchased from Sigma-Aldrich (St. Louis, MO, USA). A 
solution of MCT was prepared at 10 mg/mL, as previously reported (19). Regorafenib, a 
multikinase inhibitor, was prepared as a solution in polypropylene glycol/PEG400/Pluronic 
F68 (42.5/42.5/15 + 20% Aqua). The regorafenib compound (kindly provided by Bayer 
HealthCare Pharmaceuticals Inc. [Whippany, NJ, USA]) was stored at room temperature in 
the dark (15). Polypropylene glycol and PEG400 were purchased from Wako Pure 
Chemical Industries (Osaka, Japan). Pluronic F68 was purchased from Sigma-Aldrich. 
2.2. Animals 
We used 7–9-week-old male Sprague-Dawley rats (SLC, Shizuoka, Japan) weighing 
250–350 g. The animals had free access to food and water. All experiments were conducted 
in accordance with the guidelines for the care and use of laboratory animals of the animal 
research committee of Kyoto University. The animals received humane care in accordance 
with the NIH Guidelines for the Care and Use of Laboratory Animals. 
2.3. Experimental protocol 
MCT-treated rats were used as the experimental model of SOS (13,20,21). Rats were 
fasted for 12 h before oral administration of MCT, but had free access to water. MCT (90 
mg/kg) was administered by gavage, after which the rats were allowed to consume food 
and water ad libitum. To evaluate the efficacy of regorafenib on SOS, the rats were divided 
into 2 groups (n = 20 in each group) according to treatment with regorafenib (6 mg/kg) or 
vehicle, by oral gavage, 12 h and 36 h before MCT treatment. The administered volume of 
vehicle was the same as the volume of regorafenib. Subsequently, some of the rats were 





because the histopathological changes at 48 h after MCT treatment in rats have been found 
to be most similar to those in human SOS (21). Some animals were sacrificed and samples 
were collected at two different time points. Partial hepatectomy (30%, left lateral 
lobectomy) was performed in SOS rats treated with regorafenib or vehicle (another 15 rats 
in each group) 48 h after MCT administration. These animals were monitored for 7 days to 
examine survival after surgery, while other animals were sacrificed at 24 h after surgery. 
2.4. Histopathology 
Liver tissue samples were fixed in 4% paraformaldehyde (PFA), embedded in paraffin 
wax, and cut into 4 µm sections. Histologic assessment of SOS was performed using 
hematoxylin and eosin (H&E) staining by a single pathologist (A.M-H.) in a blinded 
manner. To quantify the degree of SOS, histological changes were scored, as previously 
reported (20,21). Sinusoidal hemorrhage, endothelial damage in the central vein, and 
coagulative necrosis of hepatocytes were graded on a 4-point scale: 0, absent; 1, mild; 2, 
moderate; and 3, severe. The total SOS score was calculated as the sum of the individual 
scores.  
2.5. Serum biochemistry 
Assessment of biologic data at 48 h after MCT treatment included serum aspartate 
transaminase (AST), alanine transaminase (ALT), and albumin (Alb) level measurements.  
2.6. Immunohistochemistry 
Endothelial cells were stained using rat endothelial cell antigen-1 (RECA-1: 
MCA-970R; AbD Serotec, Oxford, UK), as previously described (21). Tissues were 





Sections were cut at a 6-µm thickness and fixed with 4% PFA for 10 min at room 
temperature. Sections were blocked and then incubated with the primary antibody RECA-1 
at a 1:500 dilution for 1 h at 4°C. Subsequently, the sections were incubated with labeled 
polymer using an EnVision + System HRP kit (Dako, Tokyo, Japan), at room temperature 
for 1 h. The sections were examined after incubation using the Liquid DAB 
Substrate-Chromogen System (Dako). Ten high-power fields (200×) were randomly 
selected for calculating the staining area of the endothelial cells. The staining area was 
quantified using Image J (National Institutes of Health).  
For the terminal deoxynucleotidyl transferase-mediated dUTP nick end-loading 
(TUNEL) assay, we used a commercial kit (In situ Apoptosis Detection Kit; Takara Bio Inc., 
Shiga, Japan) according to the manufacturer’s instructions. TUNEL stained areas were 
examined in different locations of the tissue section in 10 low-power fields (100×) using 
Image J. 
Immunohistochemistry for cleaved caspase-3 was performed using standard protocols 
with a primary antibody that recognizes cleaved caspase-3 (Asp175) (#9102, Cell Signaling 
Technology, Inc. (CST), Danvers, MA, USA). Briefly, the sections were deparaffinized and 
quenched with hydrogen peroxide, and antigen retrieval was performed using sodium 
citrate buffer at a sub-boiling temperature for 10 minutes. Subsequently, the sections were 
incubated with primary antibodies at a 1:400 dilution overnight at 4°C, followed by 
incubation with an EnVision + System HRP kit (Dako) for 30 minutes at room temperature. 
Signals were detected using the Liquid DAB Substrate-Chromogen System (Dako), and the 





2.7. Electron microscopy 
Rats were first perfused, through the abdominal aorta, with phosphate buffered saline 
(PBS) and then with a fixative containing 2% glutaraldehyde and 4% PFA. The livers were 
cut into small pieces (approximately 1 mm3) for transmission electron microscopy (TEM) 
and into larger pieces (5 mm3) for scanning electron microscopy (SEM). The samples were 
fixed in 2% glutaraldehyde and 4% PFA at 4°C. Thin sections were stained with saturated 
uranyl acetate and lead citrate and were observed using a Hitachi H-7650 electron 
microscope for TEM. Samples were ion-sputter-coated and observed with a Hitachi S-4700 
scanning electron microscope for SEM. The following morphological changes were 
expected in the liver of rats with SOS: injured SECs with dilated fenestrae resulting in 
exposure of hepatocytes and penetration of blood cells; detachment of SECs from the 
sinusoidal wall resulting in enlargement of the space of Disse; and accumulation of blood 
cells in spaces formally occupied by hepatic sinusoids, reflecting sinusoidal congestion 
(20). 
2.8. MMP gelatin zymography 
Total protein from the whole liver was purified and 10 µg of protein was used in each 
sample. Gelatin zymography was performed using a Gelatin Zymo electrophoresis kit 
(Cosmo Bio Co., Tokyo, Japan), according to the manufacturer instructions. 
2.9. Western blot analysis 
Frozen liver tissues were homogenized in lysis buffer containing 10 mmol/L Tris–HCl 
(pH 7.4), 150 mmol/L NaCl, 1% Nonidet P-40, protease inhibitor, and phosphatase 





polyacrylamide gel electrophoresis, separated by electrophoresis, and transferred onto 
Immobilon-NC transfer membranes (Millipore Corporation, Billerica, MA, USA). After 
blocking with 5% skim milk in TBS-Tween for 1 h, the membranes were incubated with a 
primary antibody recognizing ERK (#9102, CST), phosphorylated-specific ERK (#9101, 
CST) or GAPDH (sc-25778, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) at a 
1:1000 dilution overnight at 4°C. After treating the membranes with the primary antibodies, 
a peroxidase-conjugated goat anti-rabbit IgG (sc-2004, Santa Cruz) secondary antibody was 
used at a 1:2000 dilution for 1 h at room temperature. Subsequently, bands were detected 
using ECL reagent (GE Healthcare UK Ltd., Buckinghamshire, UK) and the Ez-Capture II 
camera (ATTO, Tokyo, Japan). Results were analyzed using Image J. 
2.10. Statistical analysis 
Data were analyzed using JMP 10.0 (SAS Institute, Cary, NC, USA). The Student 
t-test was used for comparison between groups. Survival after hepatectomy was analyzed 
using the Kaplan–Meier method, and differences were evaluated using the log-rank test. P 
values of <0.05 were considered statistically significant. Data are expressed as means ± SD. 
 
3. Results 
3.1. Regorafenib attenuates MCT- induced SOS 
In the animals treated with MCT plus vehicle, macroscopic examination at 48 h after 
MCT administration showed that the liver surface was irregular, that it had turned dark red 
in color, and that bloody ascites had accumulated. These findings were less pronounced in 





displayed the typical features of SOS, with severe sinusoidal hemorrhage, sinusoidal 
dilatation, coagulative necrosis of hepatocytes, and endothelial damage in the central vein 
(Fig. 1D and E). Liver sections from the regorafenib group showed a mild degree of SOS, 
with slight sinusoidal hemorrhage and dilatation compared with the vehicle group (Fig. 1G 
and H). The SOS score in the regorafenib group was significantly lower than that in the 
vehicle group (Table 1).  
With regard to serum biochemistry evaluations at 48 h after MCT administration, AST 
and ALT levels were significantly lower in the regorafenib group than in the vehicle group. 
Furthermore, the Alb level was markedly reduced in the vehicle group compared to the 
regorafenib group (Table 1). These results suggest that regorafenib attenuated SOS.  
3.2. Regorafenib reduced necrosis in SOS liver 
Hepatocytes undergoing necrosis were detected according to morphologic criteria 
(vacuolization, loss of structure, karyolysis) with H&E staining. Moreover, to assess the 
mode of cell death, the sections were then stained using the TUNEL assay and an antibody 
against cleaved caspase-3.  
In the TUNEL assay, TUNEL-positive cells were overlapped with the necrotic areas, 
as identified by H&E staining (Fig. 1F and I). However, based on morphological criteria, 
these cells were not apoptotic. Most TUNEL-positive cells showed nuclear and, especially, 
cytoplasmic staining, which are both typically observed in cells undergoing oncotic 
necrosis (22, 23). Immunohistochemistry for cleaved caspase-3 revealed that there were 
only a few positive cells in the necrotic areas, which were detected by H&E staining and 





characteristics observed with apoptosis (23), these results indicated that necrosis was the 
main constituent of SOS-induced cell death. Thus, we defined the TUNEL-positive area as 
the area of necrosis, which was significantly decreased in the regorafenib group compared 
to the vehicle group (1.40% ± 0.21% vs. 9.62% ± 0.99%, p < 0.05; Fig. 1J).  
3.3. Regorafenib improves survival after 30% partial hepatectomy in SOS rats 
To evaluate the effect of regorafenib on remnant liver function after partial 
hepatectomy in rats with SOS, partial hepatectomy (30%) was performed in SOS rats 
treated with regorafenib or vehicle. Kaplan–Meier curves are shown in Fig. 2A. The 
survival rate at 7 days after surgery was significantly better in the regorafenib group than in 
the vehicle group (26.7% vs. 6.7%, p < 0.05), indicating that regorafenib improved survival 
after 30% hepatectomy in rats with SOS.  
To explore the cause of death after hepatectomy, histopathological examinations were 
performed in both groups at 24 h after hepatectomy (i.e., 72 h after MCT administration 
with hepatectomy). The necrotic areas were further expanded in the vehicle group (Fig. 2B) 
but not in the regorafenib group (Fig. 2C). When a hepatic resection was not performed, the 
necrotic areas were absorbed in both groups at the same time point (Fig. 2D and E), which 
reflected the stage of recovery from liver injury. These results suggested that the hepatic 
resection promoted the further development of SOS, but that regorafenib may diminish the 
extent of SOS after hepatectomy, resulting in an improvement of post-operative survival. 
3.4. Regorafenib diminished the loss of SECs due to SOS 
To quantitatively assess the impact of regorafenib on SECs, RECA-1 





examined (Fig. 3). Compared with untreated rats, areas with relative RECA-1 positivity in 
the vehicle group significantly decreased with time from 6 h to 48 h after MCT 
administration. In contrast, areas with RECA-1 positivity were significantly larger in the 
regorafenib group than in the vehicle group both at 6 h and at 48 h. These results indicated 
that regorafenib diminished the loss of SECs during the development of SOS.  
3.5. Regorafenib mitigates the SOS-induced morphological damage of SECs as observed 
on electron microscopy 
To evaluate the morphological changes of SECs in the SOS liver, electron microscopy 
was performed. SEM showed severe sinusoidal injury in the liver sections of 
vehicle-treated rats at 48 h after MCT administration: SECs were completely detached and 
lost, hepatocytes were directly exposed to sinusoids, and hepatic sinusoids were occupied 
by red blood cells (Fig. 4A). In the regorafenib group, although SEC injury with enlarged 
fenestrae was observed, SECs were preserved on the sinusoidal walls (Fig. 4B). On TEM, 
SECs were completely detached from the sinusoidal walls and blood cells had accumulated 
between SECs and hepatocytes in vehicle-treated rats (Fig. 4C). In contrast, in 
regorafenib-treated rats, part of the space of Disse was dilated, but SECs were relatively 
maintained on parenchymal cells without sinusoidal congestion (Fig. 4D). These results 
indicated that regorafenib suppressed the morphological injury of SECs during the 
development of SOS. 
3.6. Regorafenib decreases MMP-9 activity and ERK phosphorylation in SOS livers 
To assess the effect of regorafenib on MMP-9 activity in SOS livers, gelatin 





MCT treatment in the vehicle group was increased about 6.5 times from that in normal liver, 
whereas that in the regorafenib group was about 1.7 times higher than normal. Hence, the 
activity in the regorafenib group at 48 h after MCT administration was significantly lower 
than that in the vehicle group (Fig. 5 A and B). 
Phosphorylation of ERK was also examined, because it was reported to be necessary 
for MMP-9 activation (18). According to Western blot analyses of phosphorylated-ERK 
and total ERK, the relative ratio of p-ERK protein expression to total ERK protein 
expression in the vehicle group at 6 h after MCT administration was increased about 
twofold compared to that of the normal rats (p<0.001). In contrast, the relative ratio of 
p-ERK/ERK in the regorafenib group was significantly attenuated compared with the 
vehicle group (1.21 ± 0.32 vs. 2.09 ± 0.44, p<0.01) and was equivalent to that of the normal 
rats (Fig. 5 C and D). These results suggested that regorafenib decreased MMP-9 activation 
and ERK phosphorylation in SOS liver.  
 
4. Discussion 
SOS is a form of drug-induced liver injury caused by ingestion of pyrrolidine alkaloids 
and cytotoxic drugs such as azathioprine, cyclophosphamide, busulfan, and dacarbazine. It 
was initially considered a complication of high-dose chemotherapy used as conditioning 
regimens for bone marrow transplantation for hematologic malignancies (24) and is now a 
well-known contributor to morbidity and mortality after stem cell transplantation (25). For 
patients with CLM, Rubbia-Brandt et al. first described SOS as a significant hepatic 





biological markers have been shown to be related to SOS, such as tumor necrosis factor 
(TNF)-alpha, interleukin (IL)-1b, IL-8, soluble IL-2 receptor, fibrin, fibrinogen, von 
Willebrand factor, thrombomodulin, and vascular endothelial growth factor (VEGF) (25,26), 
it was unclear whether these are crucial mediators or consequent features in the process of 
SOS. Several previous articles have attempted to clarify the precise mechanism of SOS 
development using a rat model of SOS. DeLeve et al. reported the use of a rat model in 
which SOS was induced by MCT, a pyrrolizidine alkaloid, with reproducible results (20). 
The authors have described the mechanism of SOS in their rat model and in vitro as follows 
(12,20,27). MCT is metabolically activated to MCT pyrrole, which binds to F-actin in SECs 
and disassembles it. Disassembly of F-actin leads to rounding up of SECs and upregulation 
of MMP-9. Mechanical stress due to blood flow separates SECs from the underlying 
parenchymal cells, with subsequent embolization of the sinusoids, and MMP-9 
upregulation facilitates degeneration of the extracellular matrix in the space of Disse, 
expediting SEC detachment from the sinusoidal walls. These microvascular injuries induce 
typical features of SOS such as sinusoidal dilatation, endothelial damage in the central vein, 
and coagulative necrosis of hepatocytes.  
In the current study, histopathological examination and serum biochemistry revealed 
that regorafenib attenuated SOS, in concurrence with suppression of ERK phosphorylation 
and MMP-9 activity. While MMP-9, a collagenase that degrades extracellular matrix and 
basement membrane components (28), is considered a crucial factor in accelerating the 
development of SOS, degenerating extracellular matrix in the space of Disse, and 





necessary for MMP-9 expression (18). In the current study, we first demonstrated that ERK 
1/2 was phosphorylated in MCT-induced SOS. Since a previous report indicated that 
regorafenib inhibits ERK1/2 phosphorylation through the inhibition of the Raf/MEK/ERK 
pathway (15), we considered that regorafenib attenuated MMP-9 activity through the 
inhibition of ERK phosphorylation in this study. Previously, we demonstrated that c-Jun 
N-terminal kinase (JNK) was phosphorylated in the liver after treatment with MCT and that 
sorafenib reduced the severity of SOS by attenuating the activation of MMP-9 through the 
inhibition of the phosphorylation of JNK (13). However, another study reported that 
regorafenib did not inhibit the phosphorylation of JNK (29), suggesting that regorafenib 
might inhibit the activation of MMP-9, which was independent of JNK. RECA-1 
immunostaining in this study showed that SECs were relatively preserved in 
regorafenib-treated rats compared to vehicle-treated rats at two time points; however, at 48 
h after MCT administration, the rats in the regorafenib group also showed reduced 
preservation of SECs compared with normal rats. These results suggest that regorafenib 
indeed significantly attenuated the loss of SECs from the sinusoidal walls, but did not 
completely prevent this loss. During the development of SOS, the embolization of detached 
SECs induces congestion of the sinusoid and microcirculatory disturbance, resulting in the 
typical histopathological features of SOS. Because regorafenib reduces the detachment of 
SECs in the early phase, it might lead to an improvement in the severity of SOS in the 
advanced phase. Electron microscopic evaluation in this study also showed that 
enlargement of the space of Disse and separation of SECs from parenchymal cells were 





parenchymal cells and drained away in the vehicle group. These effects for the preservation 
of SECs in the regorafenib group might have been induced by suppression of the 
ERK/MMP-9-related pathway, which promotes SOS and is a crucial but not the sole 
mechanism in the loss of SECs. Moreover, Topp et al. reported that MMP-9 itself was 
involved in the morphological injury of SECs, in a manner related to actin disassembly, 
although actin disassembly has been shown to be necessary for the secretion of MMP-9 
(30). Electron microscopic images in our study also showed that the morphology of SECs 
was comparatively preserved in regorafenib-treated rats, with suppression of MMP-9 
activity. MMP-9 might independently promote morphologic SEC damage, in addition to 
inducing extracellular matrix degeneration.  
Associated with recent developments in chemotherapy for colorectal cancer, newly 
developed drugs including oxaliplatin produce high response rates in patients with CLM, 
ranging from 43% to 60% (31,32,33), compared with the rates of traditional drugs, which 
range from 18% to 30% (34,35). A recent study reported that 22.5% of patients with 
initially unresectable CLM underwent curative resection following neoadjuvant 
chemotherapy and that their overall survival was comparable to that of patients with 
resectable CLM (36). The incidence of hepatic resection following neoadjuvant 
chemotherapy in patients with CLM may therefore increase in the future. In patients with 
CLM, SOS is detected in 51–64% of patients after oxaliplatin-based chemotherapy 
(9,37,38) and is a serious concern because of its adverse effects. Vreuls et al. reported that a 
higher grade of SOS was associated with a lower tumor response to neoadjuvant oxaliplatin 





hepatectomy in patients with CLM (10). Tamandl et al. showed that SOS led to early 
recurrence and decreased survival in the long term (39). These reports highlight the 
importance of a strategy for the prevention of SOS. To date, several studies have 
demonstrated that bevacizumab, a humanized anti-VEGF monoclonal antibody, has a 
protective effect against oxaliplatin-induced SOS (40,41,42); however, the mechanism of 
prevention is still unclear and the validity of this effect has been questioned (43). In a rat 
model of SOS, MMP inhibitors, phosphodiesterase (PDE) III inhibitors, and sorafenib have 
been reported to prevent SOS (12,13,21); however, MMP inhibitors and PDE III inhibitors 
are not widely used to treat SOS in humans. Sorafenib is a multikinase inhibitor approved 
for the treatment of hepatocellular carcinoma and renal cell carcinoma around the world, 
although it is not used in combination with oxaliplatin for colorectal cancer at present, and 
the probability of its future application is low because of the unsatisfactory results obtained 
in clinical studies (14).  
Regorafenib is the first small-molecule kinase inhibitor to show efficacy against 
metastatic colorectal cancer (16). Currently, it is approved for metastatic colorectal cancer 
as monotherapy; furthermore, it potentially has additional therapeutic value as combined 
therapy with oxaliplatin as first- or second-line therapy, based on the results of clinical 
trials (17). Our results suggested that hepatic resection may cause shear stress on the SOS 
liver, which may accelerate the loss of SECs, resulting in the further development of SOS 
and death after hepatic resection. Because regorafenib suppresses SOS at the time of 
hepatectomy, regorafenib might diminish the deterioration caused by SOS after 





if combined treatment with regorafenib and oxaliplatin is approved as being effective for 
CLM, this combination is potentially desirable from two viewpoints. First, the addition of 
regorafenib to oxaliplatin treatment would bring the advantage of an anticancer effect, and 
the intense pharmacological effect might allow patients with initially unresectable CML to 
undergo hepatectomy with the intent to cure. Second, the addition of regorafenib would 
suppress oxaliplatin-induced SOS, help reduce morbidity, and enable additional patients 
with unresectable CML due to insufficient remnant liver function to become candidates for 
curative hepatic resection. However, it is premature to directly apply our findings from an 
animal study to humans. Hence, further studies and the results from human clinical trials 
are needed before we arrive at a definitive conclusion.  
There are several limitations in our study. First, the precise mechanism of SOS and the 
manner in which regorafenib mitigates SOS have not yet been precisely clarified. We may 
have only demonstrated one of the possible pathways because regorafenib is a multi-kinase 
inhibitor that may affect various kinase pathways that are also involved in SOS 
development. Second, the rat SOS model that we used in this study has been reported to 
mimic the histopathological features of human SOS (20,21). Because MCT-induced liver 
injury was acute and severe, this animal model may be somewhat different from 
oxaliplatin-induced SOS in humans. Therefore, further investigations and clinical 
evaluations are necessary. 
In conclusion, the results of the present study show that regorafenib diminishes 
MCT-induced SOS in rats, concomitant with the inhibition of ERK phosphorylation and 





in survival following hepatectomy in rats with SOS. These results suggest that pretreatment 
with regorafenib may constitute a therapeutic strategy to prevent SOS in patients with CLM 
in addition to facilitating an antitumor effect. Data from ongoing clinical trials may help to 
confirm our findings. 
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Fig. 1 Effect of regorafenib on liver pathology in monocrotaline-induced sinusoidal 
obstruction syndrome in rats. Hematoxylin and eosin (H&E) staining of a normal rat liver 
(A: 40×, B: 200×). H&E staining in a vehicle-treated rat showed sinusoidal hemorrhage and 
dilatation (arrow head), coagulative necrosis of hepatocytes (white arrow), and endothelial 
damage of the central vein (black arrow) (D: 40×, E: 200×). H&E staining in a 
regorafenib-treated rat (G: 40×, H: 200×). No TUNEL-positive cells were identified in 
the normal rat samples (C). The TUNEL-positive cells coincided with the necrotic areas 
identified by H&E staining in a vehicle-treated rat (F) and in a regorafenib-treated rat (I). 
(J) Areas of relative necrosis at different locations of the tissue section in 10 low-power 
fields (n = 9 in each group). MCT, monocrotaline; VHC, vehicle; REGO, regorafenib; *p < 
0.05. 
Fig. 2 Effect of regorafenib on survival after partial hepatectomy.  (A) Kaplan-Meier 
curves for 7 days after partial hepatectomy (30%) in the regorafenib group (gray line) and 
vehicle group (black line) (n = 15 in each group). The survival rate at 7 days after surgery 
was significantly higher in the regorafenib group than in the vehicle group (26.7% vs. 6.7%, 
p < 0.05). Hematoxylin and eosin (H&E) staining (100×) in a vehicle-treated rat at 24 h 
after hepatectomy (i.e., at 72 h after MCT administration) (B) showed further expansion of 
the necrotic area, unlike in a regorafenib-treated rat (C). H&E staining (100×) in a 
vehicle-treated rat (D) and in a regorafenib-treated rat (E) at 72 h after MCT administration 
without hepatectomy showed the absorption of the necrotic areas.  
Fig. 3 Effect of regorafenib on the loss of sinusoidal endothelial cells in sinusoidal 
26 
obstruction syndrome rats. (A) Areas of relative RECA-1 positivity at different locations 
of the tissue section in 10 high-power fields (200×) at 6 h and 48 h after MCT 
administration in the regorafenib group (gray line) and vehicle group (black line) (n = 5 in 
each). *p < 0.05 between the two groups; #p < 0.05 compared with normal rats. (B) 
Representative images of immunohistochemistry for RECA-1 in a normal rat and in a rat 
treated with regorafenib or vehicle at 6 h and 48 h after MCT administration. RECA-1, rat 
endothelial cell antigen 1; MCT, monocrotaline; VHC, vehicle; REGO, regorafenib.  
Fig. 4 Electron microscopy images. (A) SEM in the vehicle group (2000×). (B) SEM in 
the regorafenib group (3000×). (C) TEM in the vehicle group (2000×). (D) TEM in the 
regorafenib group (2000×). All samples were collected at 48 h after MCT treatment. The 
scale bars correspond to 2 µm. The arrow indicates an enlarged fenestration in SECs. S, 
sinusoidal endothelial cell; D, space of Disse; MCT, monocrotaline; VHC, vehicle; REGO, 
regorafenib; SEM, scanning electron microscopy; TEM, transmission electron microscopy. 
Fig. 5 Activity of MMP-9 and expression of ERK and phosphorylated ERK. (A) The 
relative MMP-9 activity in the liver tissue from gelatin zymography quantified by 
densitometry in the regorafenib group and vehicle group at 48 h after MCT treatment (n = 5 
in each group). (B) Representative image of gelatin zymography in a regorafenib-treated rat 
and in a vehicle-treated rat. (C) The relative ratio of p-ERK/ERK in the liver tissue based 
on western blot analysis and quantified by densitometry in the regorafenib group and 
vehicle group at 6 h after MCT treatment (n = 5 in each group). (D) Representative images 
of western blot analysis of ERK, p-ERK and GAPDH in a regorafenib-treated rat and in a 
vehicle-treated rat. MMP-9, matrix metalloproteinase-9; ERK, extracellular 
27 
signal-regulated kinase; p-ERK, phosphorylated extracellular signal-regulated kinase; MCT, 
monocrotaline; VHC, vehicle; REGO, regorafenib; N.S., not significant; *p < 0.05, **p < 
0.001.  
Fig. A.1 Immunostaining of cleaved caspase-3. No cleaved caspase 3-positive cells were 
identified in liver from a normal rat (A). Only a few cells were identified as positive for 
cleaved caspase-3 (arrow) in the necrotic areas in a vehicle-treated rat (B) and in a 
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*p<0.05 *p<0.05, **p<0.001Fig. 5
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Fig. A.1
Table 1 SOS score for HE staining and serum biochemistry at 48 h after MCT 
administration 
 MCT+vehicle MCT+regorafenib p 
SOS score 8.20±1.36 7.05±1.96 <0.05 
AST [IU/L] 5484±2685 3100±1400 <0.01 
ALT [IU/L] 2389±1159 1736±798 <0.05 
Alb [g/dl] 3.10±0.21 3.29±0.20 <0.01 
 
Data are shown as means ± SD. n=20 in each group 
SOS, sinusoidal obstruction syndrome; HE, hematoxylin and eosin; MCT, 
monocrotaline; AST, aspartate aminotransferase; ALT, alanine aminotransferase; Alb, 
albmine. 
 
 
 
 
 
 
 
 
